Dutch rare diseases biotech firm ProQR Therapeutics (Nasdaq: PRQR) today announced the appointment of Dr Cristina Lopez Lopez as chief medical officer (CMO).
It also named Dennis Hom as chief financial officer (CFO). These key leadership appointments support the advancement of the company’s Axiomer platform technology and pipeline of RNA editing programs as it enters the clinical stage, said ProQR.
Jurriaan Dekker, currently CFO and chief corporate development officer René Beukema will be stepping down from their roles, having played key roles in supporting the Company’s strategic transition to a focused RNA editing platform. Both executives will remain with the company during a transitional period to ensure continuity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze